Anavex life sciences provides supplemental information on anavex®2-73 (blarcamesine) avatar phase 3 trial for the treatment of adult patients with rett syndrome

New york, feb. 04, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today provides supplemental information on the anavex®2-73 (blarcamesine) avatar phase 3 trial for the treatment of adult patients with rett syndrome.
AVXL Ratings Summary
AVXL Quant Ranking